Effects of nintedanib in patients with SSc-ILD and preserved and highly impaired lung function

W. Wuyts (Leuven, Belgium), A. Azuma (Tokyo, Japan), J. Distler (Erlangen, Germany), K. Sondergaard (Aarhus, Denmark), S. Proudman (Adelaide, Australia), V. Cottin (Lyon, France), E. Erhardt (Sulzbach, Germany), M. Quaresma (Ingelheim am Rhein, Germany), M. Gahlemann (Basel, Switzerland), M. Alves (Ingelheim am Rhein, Germany), T. Maher (London, United Kingdom)

Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
W. Wuyts (Leuven, Belgium), A. Azuma (Tokyo, Japan), J. Distler (Erlangen, Germany), K. Sondergaard (Aarhus, Denmark), S. Proudman (Adelaide, Australia), V. Cottin (Lyon, France), E. Erhardt (Sulzbach, Germany), M. Quaresma (Ingelheim am Rhein, Germany), M. Gahlemann (Basel, Switzerland), M. Alves (Ingelheim am Rhein, Germany), T. Maher (London, United Kingdom). Effects of nintedanib in patients with SSc-ILD and preserved and highly impaired lung function. 3393

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A rejuvenation effect of the antifibrotic therapy correlates with lung function improvement in IPF patients
Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases
Year: 2021


Effect of low dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real life study
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021


Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function
Source: Eur Respir J 2016; 48: 843-851
Year: 2016



COPD patients exhibit abnormally increased peripheral neutrophil stiffening not different from smokers with normal lung function
Source: Annual Congress 2009 - Functional insights into COPD
Year: 2009

The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016

Cilomilast decreases exacerbations and maintains lung function in patients with poorly reversible COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 88s
Year: 2004

Short-term dynamic lung function and predictors of lung function decline in systemic sclerosis-related interstitial lung disease
Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020


The effects of sildenafil on lung function in COPD
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012

Effect of baseline FVC on lung function decline with nintedanib in patients with IPF
Source: International Congress 2015 – Treatment of IPF
Year: 2015



The effect of everolimus on lung function and renal status in lung transplanted patients
Source: International Congress 2016 – Post-transplant complications: from animal models to the bedside
Year: 2016

Reduced exercise capacity and impaired pulmonary function in patients with scleroderma
Source: Annual Congress 2010 - Different patterns of diffuse parenchymal lung disease
Year: 2010

Enoxaparin elicits an effect on lung function and blood gas levels in patients with COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 342s
Year: 2004

The effect of nintedanib compared to pirfenidone on proliferation of lung fibroblasts from patients with IPF
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015


Diaphragm dysfunction in combination with lung function decline is associated with higher mortality in idiopathic pulmonary fibrosis patients
Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias
Year: 2018

Relationships between angiogenic activity of sera from interstitial lung disease (ILD) patients and lung function tests
Source: Eur Respir J 2002; 20: Suppl. 38, 106s
Year: 2002

Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment
Source: International Congress 2016 – IPF treatment I
Year: 2016


Effect of smoking on lung functions in patients with COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 157s
Year: 2005

Leptin levels are associated with reduced lung function in men with COPD
Source: Virtual Congress 2021 – COPD burden, epidemiology and management
Year: 2021


Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial
Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Year: 2019


LAMA increases pulmonary lung functions in post-tuberculous destroyed lung patients
Source: International Congress 2018 – Pulmonary tuberculosis: long term complications, rehabilitation and challenges
Year: 2018